Inve US ▾
SOSOLV

Solventum (SOLV) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· Health Care· May 5, 2026

Source: earnings call transcript

Executive summary

Solventum Q1 FY26 — Strong Start, Ahead of Plan, Accelerated Buybacks

Solventum delivered a strong first quarter, exceeding sales and earnings expectations, driven by solid commercial execution, new product launches, and operational efficiencies. The company is making significant progress on its separation from 3M and portfolio optimization, including accelerating share repurchases. Management expressed confidence in achieving full-year guidance and long-range plan targets, despite navigating ongoing separation efforts and macro headwinds.

Highlights

5

  • Organic sales growth of 2.1% exceeded plan and expectations.

  • Adjusted EPS of $1.48 grew 11% year-over-year, ahead of expectations.

  • Gross margins improved 80 basis points year-over-year to 56.4%.

  • Acera acquisition contributed $28 million to reported sales in Advanced Wound Care.

  • Repurchased 923,000 shares for $67 million in Q1 FY26.

Concerns

2

  • Annual tariff headwinds are expected to be $100 million to $120 million.

  • A sales timing benefit of over $100 million is expected in Q2 due to ERP cutover, which will reverse in Q3.

Guidance & targets

CategoryTargetConfidence
Full-year organic sales growth
Maintained
high materiality
High
Full-year free cash flow
Maintained
high materiality
High
Full-year adjusted EPS
Toward the high end of $6.40 to $6.60 range
high materiality
High
Full-year operating margin
21% to 21.5%
high materiality
High
Full-year effective tax rate
19.5% to 20.5%
medium materiality
High
Annual tariff headwinds
$100 million to $120 million
high materiality
High
Operating margin expansion
50 to 100 basis points
high materiality
High
ERP cutover sales timing benefit
Over $100 million
medium materiality
High
Long-range plan organic sales growth
4% to 5%
high materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
MedSurg
Strong underlying performance in growth driver areas, including Negative Pressure Wound Therapy. Acera acquisition opens doors to fast-growth acute care synthetic tissue space. Infection Prevention and Surgical Solutions performed well despite a tough prior-year comparison.
Advanced Wound Care organic growth: 2.1%Acera contribution to reported sales: $28 millionInfection Prevention and Surgical Solutions organic growth: 0.6%
$1.2 billion1.2%——
Dental Solutions
Growth driven by innovation and separation-related timing benefits. Core restoratives led performance, leveraging new product launches and improved back orders.
$354 million3.4%——
Health Information Systems
Strong results driven by Revenue Cycle Management and Performance Management solutions. Autonomous coding continues to gain traction, with international expansion providing a tailwind. Clinician Productivity Solutions experienced expected declines.
Clinician Productivity Solutions decline: double-digit
$342 million4.7%——

SOLV operating KPIs by quarter

SOLV operating KPIs stated on its earnings calls, by fiscal quarter
KPI Dec 2025 Q4 FY25This call Mar 2026 Q1 FY26Change vs prior quarter
Distribution centers
55 Regarding supply chain, we've taken further steps to separate from 3M and have now reduced our distribution center network to 55 locations, progressing towards our goal of 45. Source: earnings call transcript
54 With further work to streamline our distribution centers, we are now down to 54 worldwide. Source: earnings call transcript
-1.8%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Product announcements

ProductTypeDetails
Clarity brandlaunch
Filtek Easy Matchlaunch
Clinpro Clearlaunch
Test sterilization productslaunch
V.A.C Peel and Place Dressingexpansion

Deals & partnerships

Acera Acquisition of a fast-growth business aligned to existing call points, specifically in the acute care synthetic tissue space.

Early integration is playing out as expected, reinforcing ability to identify, close, and integrate attractive assets. Slots perfectly into Advanced Wound Care infrastructure.

Purification and Filtration (P&F) business Divestiture of the Purification and Filtration business. $4 billion

Separation is progressing well, with the majority of transition service agreements to be completed in 2027. Described as one of the best multiples in the sector.

Risks & headwinds

Annual tariff headwinds FY26

$100 million to $120 million

Mitigation:Active supply chain mitigation strategies; Transform for the Future program provides additional firepower to offset headwinds.

Inflationary impacts FY26

Unquantified

Mitigation:Offset by programmatic savings and portfolio moves, contributing to operating margin expansion.

ERP cutover sales timing reversal Q3 FY26

Over $100 million sales benefit in Q2 expected to reverse in Q3

Mitigation:Advanced ordering strategy with customers and distributors to mitigate challenges during the U.S. and Canada ERP cutover in Q3. High proportion of sales through distribution in the U.S. provides a strong contingency.

Separation-related timing benefits Q1 FY26

70 basis points of sales volume accelerated from Q2 into Q1

Mitigation:Managed through advanced orders to keep customers stocked during registration blackouts and other separation activities.

What to watch in Q2 FY26

ERP cutover sales reversal

Q3 FY26
Current Over $100M sales benefit in Q2
Target Quantification of reversal in Q3

Why it matters

This will impact Q3 reported sales and requires careful adjustment for underlying growth analysis.

We estimate over $100 million of sales timing benefit in Q2 that we expect will reverse in 2026, mostly in Q3.

Find out whether SOLV delivers this. Inve re-checks your case every morning.

Q&A highlights

Clarification on the expected $100M sales benefit in Q2 due to ERP cutover, specifically which segments will be impacted and how to model it.

The $100M+ sales benefit in Q2 is due to advanced orders from customers/distributors ahead of the Q3 U.S. and Canada ERP cutover, primarily impacting IP&SS and Dental. This is a mitigation strategy to ease the transition. The full-year guidance remains unchanged, as the Q2 benefit is expected to reverse in the second half, mostly Q3. Management advises against modeling the precise Q2 impact, promising an update with actuals.

“So as we called out in the prepared remarks, as you said, Brett, we are estimating over $100 million additional sales in Q2 as we're working with our customers and distributors to advance orders before we begin our Q3 cutover of ERPs in the U.S. and Canada. This is going to mostly impact IPSS and Dental to your question.”

asked by Brett Fishbin · answered by Wayde McMillan

2 min read 5 chapters

Detailed narrative

Operational Efficiency and Separation Progress

Solventum is making significant strides in its separation from 3M, having exited over 50% of transition service agreements (TSAs) and on track to exit over 90% by the end of 2026. The company successfully migrated 75% of its 1,200+ system applications, including a recent ERP cutover in Asia Pacific. Further facility moves, manufacturing expansion in South Dakota, and distribution center streamlining (down to 54 worldwide) are enhancing supply chain flexibility and operational efficiency.

Portfolio Optimization and Capital Allocation

The company views portfolio optimization as a perpetual lever for value creation, demonstrated by SKU rationalization (more than halfway complete), the divestiture of the P&F business, and the acquisition of Acera. Acera, a fast-growth business aligned with existing call points, contributed $28 million in Q1 sales. Solventum has Board approval for up to $1 billion in share buybacks and plans to accelerate execution, balancing it with tuck-in acquisitions in a 'target-rich environment'.

Commercial Momentum and Innovation Pipeline

Solventum's underlying commercial momentum is strong, reinforced by a rebuilt commercial engine with clearer accountability and specialized sales teams. Innovation is fueling this momentum, with close to 20 new products expected to launch over the next two years, primarily in growth driver areas. These launches are designed as a steady cadence of 'singles, doubles, and triples' to reduce risk and provide consistent fuel for the commercial teams.

Health Information Systems and Autonomous Coding

The Health Information Systems (HIS) segment continues to perform strongly, driven by Revenue Cycle Management (RCM) and Performance Management solutions. The autonomous coding offering is gaining traction in both outpatient and inpatient settings, leveraging Solventum's unique data sets, rules, and algorithms to train AI for accurate and compliant reimbursement coding. The company believes 80-90% of coding can eventually be autonomous, targeting 50% customer adoption during the strategic plan period due to compelling economics (productivity, FTE reduction, improved revenue capture).

Gross Margin Strength and Future Outlook

Despite tariff and inflationary headwinds, Q1 gross margins improved 80 basis points year-over-year to 56.4%, exceeding expectations due to programmatic savings, favorable portfolio moves, sales leverage, and mix. While Q1 benefited from these factors, management expects gross margins to normalize slightly below 56% for the remainder of the year. The Transform for the Future program, a multiyear $500 million savings initiative, is designed to proactively reshape the operating structure and offset headwinds, contributing to the committed 50-100 basis point operating margin expansion in 2026.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.